anti-human VEGFR-3/FLT-4 monoclonal antibody Anti-Human 50 µg
Description / anti-human VEGFR-3/FLT-4 monoclonal antibody
The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.
More Information
| Size | 50 µg |
|---|---|
| Source | Mouse |
| Isotype | IgG1 |
| Biological Activity | WB: Use at 2-5 µg/ml; ELISA: Use at 1-10 µg/ml; IP: use at 2-10 µg/ml. |
| Clone Nr. | (#1(9D9)) |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% |
| Preparation | The antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain. The |
| Antigen | recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain |
| Application | E, WB, IP |
| Synonyms | vascular endothelial growth factor receptor-3; FLT4; PCL; LMPH1A; VEGFR3; fms-related tyrosine kinase 4 |
| Uniprot ID | P35916 |
| Protein RefSeq | NP_002011 |
| mRNA RefSeq | NM_002020 |